Amsterdam Molecular Therapeutics (AMT) Holding N.V. – Product Pipeline Review – Q1 2011

Date: March 1, 2011
Pages: 62
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Brief Review
Delivery: E-mail Delivery (PDF)
ID: A7BCEEA90FDEN
Leaflet:

Download PDF Leaflet

Amsterdam Molecular Therapeutics (AMT) Holding N.V. - Product Pipeline Review - Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “Amsterdam Molecular Therapeutics (AMT) Holding N.V. - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Amsterdam Molecular Therapeutics (AMT) Holding N.V. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Amsterdam Molecular Therapeutics (AMT) Holding N.V. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Amsterdam Molecular Therapeutics (AMT) Holding N.V. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Amsterdam Molecular Therapeutics (AMT) Holding N.V.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Evaluate Amsterdam Molecular Therapeutics (AMT) Holding N.V.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Amsterdam Molecular Therapeutics (AMT) Holding N.V. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Amsterdam Molecular Therapeutics (AMT) Holding N.V.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Amsterdam Molecular Therapeutics (AMT) Holding N.V..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Amsterdam Molecular Therapeutics (AMT) Holding N.V. and identify potential opportunities in those areas.
Table of Contents
List of Tables
List of Figures
Amsterdam Molecular Therapeutics (AMT) Holding N.V. Snapshot
Amsterdam Molecular Therapeutics (AMT) Holding N.V. Overview
Key Information
Key Facts
Amsterdam Molecular Therapeutics (AMT) Holding N.V. – Research and Development Overview
Key Therapeutic Areas
Amsterdam Molecular Therapeutics (AMT) Holding N.V. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Amsterdam Molecular Therapeutics (AMT) Holding N.V. – Pipeline Products Glance
Amsterdam Molecular Therapeutics (AMT) Holding N.V. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Amsterdam Molecular Therapeutics (AMT) Holding N.V. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Amsterdam Molecular Therapeutics (AMT) Holding N.V.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Amsterdam Molecular Therapeutics (AMT) Holding N.V. – Drug Profiles
Glybera
Product Description
Mechanism of Action
R&D Progress
Glybera
Product Description
Mechanism of Action
R&D Progress
AMT-060
Product Description
Mechanism of Action
R&D Progress
AMT-021
Product Description
Mechanism of Action
R&D Progress
AMT-030
Product Description
Mechanism of Action
R&D Progress
AMT-050
Product Description
Mechanism of Action
R&D Progress
AMT-070
Product Description
Mechanism of Action
R&D Progress
AMT-080
Product Description
Mechanism of Action
R&D Progress
AMT-090
Product Description
Mechanism of Action
R&D Progress
Amsterdam Molecular Therapeutics (AMT) Holding N.V. – Pipeline Analysis
Amsterdam Molecular Therapeutics (AMT) Holding N.V. – Pipeline Products by Therapeutic Class
Amsterdam Molecular Therapeutics (AMT) Holding N.V. - Pipeline Products By Target
Amsterdam Molecular Therapeutics (AMT) Holding N.V. – Pipeline Products by Route of Administration
Amsterdam Molecular Therapeutics (AMT) Holding N.V. – Pipeline Products by Molecule Type
Amsterdam Molecular Therapeutics (AMT) Holding N.V. – Recent Pipeline Updates
Amsterdam Molecular Therapeutics (AMT) Holding N.V. - Dormant Projects
Amsterdam Molecular Therapeutics (AMT) Holding N.V. – Company Statement
Amsterdam Molecular Therapeutics (AMT) Holding N.V. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Sep 24, 2010: AMT Receives FDA Orphan Drug Designation For Duchenne Muscular Dystrophy Gene Therapy
Aug 18, 2010: AMT's Marketing Authorization Application For Glybera Progressing On Schedule
Nov 11, 2009: AMT Announces Successful Results In Preclinical Treatment Of AMT-080 For Duchenne Muscular Dystrophy (DMD)
Oct 13, 2009: AMT Receives EMEA Orphan Drug Designation For AMT-080 For The Treatment Of Duchenne Muscular Dystrophy
May 01, 2007: Amsterdam Molecular Therapeutics BV to Present Preclinical Proof-of-concept Data On Its Gene Therapy AMT-020 To Treat Acute Intermittent Porphyria
Apr 28, 2007: Amsterdam Molecular Therapeutics BV Receives Global Rights To Develop And Commercialize AMT-020 For Acute Intermittent Porphyria
Sep 01, 2003: AMT Receives EUR 1.8 M For Ex Vivo IL-10 Gene Therapy Programme In Crohn's Disease
Financial Deals Landscape
Amsterdam Molecular Therapeutics (AMT) Holding N.V., Deals Volume Summary, 2004 to YTD 2011
Amsterdam Molecular Therapeutics (AMT) Holding N.V., Deals Summary By Region, 2004 to YTD 2011
Amsterdam Molecular Therapeutics (AMT) Holding N.V., Deals Summary, 2004 to YTD 2011
Amsterdam Molecular Therapeutics (AMT) Holding N.V. Detailed Deal Summary
Asset Purchase
Amsterdam Molecular Therapeutics Acquires Sales Rights Of Lipoprotein From Essential Medical Treatments
Venture Financing
Amsterdam Molecular Therapeutics Raises $28 Million In Series A Financing
Equity Offering
Amsterdam Molecular Therapeutics Completes Initial Public Offering Of $75 Million
Debt Offering
Amsterdam Molecular Therapeutics Completes Private Placement Of Convertible Bonds For $7 Million
Amsterdam Molecular Therapeutics Enters Into An Agreement With Progenika Biopharma
Amsterdam Molecular Therapeutics Enters Into Agreement With St. Jude Children’s Research Hospital
Amsterdam Molecular Therapeutics Enters Into Co-Development Agreement With National Institutes of Health
Amsterdam Molecular Therapeutics Enters Into Research Collaboration With University of Barcelona
Amsterdam Molecular Therapeutics Enters Into Agreement With Galapagos, Vrije Universiteit Amsterdam And The Netherlands Institute for Brain Research
Licensing Agreements
Amsterdam Molecular Therapeutics Enters Into Licensing Agreement With Amgen
Amsterdam Molecular Therapeutics Enters Into Licensing Agreement With Sapienza University of Rome
Amsterdam Molecular Therapeutics Enters Into Licensing Agreement With University of Navarra
Amsterdam Molecular Therapeutics Enters Into Licensing Agreement With Targeted Genetics
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Amsterdam Molecular Therapeutics (AMT) Holding N.V. – Pipeline by Therapy Area and Indication, 2011
Amsterdam Molecular Therapeutics (AMT) Holding N.V. – Pipeline by Stage of Development, 2011
Amsterdam Molecular Therapeutics (AMT) Holding N.V. – Monotherapy Products in Pipeline, 2011
Amsterdam Molecular Therapeutics (AMT) Holding N.V. – Filed, 2011
Amsterdam Molecular Therapeutics (AMT) Holding N.V. – Phase III, 2011
Amsterdam Molecular Therapeutics (AMT) Holding N.V. - Phase II, 2011
Amsterdam Molecular Therapeutics (AMT) Holding N.V. - Pipeline By Therapeutic Class, 2011
Amsterdam Molecular Therapeutics (AMT) Holding N.V. - Pipeline By Target, 2011
Amsterdam Molecular Therapeutics (AMT) Holding N.V. – Pipeline By Route of Administration, 2011
Amsterdam Molecular Therapeutics (AMT) Holding N.V. – Pipeline By Molecule Type, 2011
Amsterdam Molecular Therapeutics (AMT) Holding N.V. – Recent Pipeline Updates, 2011
Amsterdam Molecular Therapeutics (AMT) Holding N.V. - Dormant Developmental Projects, 2010
Amsterdam Molecular Therapeutics (AMT) Holding N.V., Subsidiaries
Amsterdam Molecular Therapeutics (AMT) Holding N.V., Deals Summary, 2004 to YTD 2011
Amsterdam Molecular Therapeutics (AMT) Holding N.V., Deals Summary by Region, 2004 to YTD 2011
Amsterdam Molecular Therapeutics (AMT) Holding N.V., Deals Summary, 2004 to YTD 2011

LIST OF FIGURES

Amsterdam Molecular Therapeutics (AMT) Holding N.V. – Pipeline by Therapy Area and Indication, 2011
Amsterdam Molecular Therapeutics (AMT) Holding N.V. – Pipeline by Stage of Development, 2011
Amsterdam Molecular Therapeutics (AMT) Holding N.V. – Monotherapy Products in Pipeline, 2011
Amsterdam Molecular Therapeutics (AMT) Holding N.V. – Pipeline By Therapeutic Class, 2011
Amsterdam Molecular Therapeutics (AMT) Holding N.V. – Pipeline By Route of Administration, 2011
Amsterdam Molecular Therapeutics (AMT) Holding N.V. – Pipeline By Molecule Type, 2011

Ask Your Question

Amsterdam Molecular Therapeutics (AMT) Holding N.V. – Product Pipeline Review – Q1 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: